Roivant Sciences Ltd.
ROIV Nasdaq
SEC CIK 1635088
Follow Roivant Sciences Ltd.
Weekly email: filings, results
Revenue, last quarter
$35.1M
+2135.6% vs same quarter last year
Net income
−$191.6M
−68.8% vs same quarter last year
EPS, diluted
−$0.27
−58.8% vs same quarter last year
Operating cash flow
$594.4M
+420.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $8.3M | −$299.8M |
| FY25 | $29.1M | −$172M |
| FY24 | $32.7M | $4.3B |
| FY23 | $31.5M | −$1B |
| FY22 | $55.3M | −$845.3M |
| FY21 | $23.8M | −$809.2M |
| FY20 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY26 | −6235.7% | −3629.2% |
| FY25 | −3453.3% | −592% |
| FY24 | 13746.9% | 13294.2% |
| FY23 | −2875.9% | −3200.2% |
| FY22 | −2444.8% | −1528.9% |
| FY21 | −4500.5% | −3400.9% |
| FY20 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | −$758.6M |
| FY25 | −$844.1M |
| FY24 | −$766.7M |
| FY23 | −$856.1M |
| FY22 | −$695.2M |
| FY21 | −$557.9M |
| FY20 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY26 | - |
| FY25 | $1.3B |
| FY24 | $0 |
| FY23 | $0 |
| FY22 | - |
| FY21 | - |
| FY20 | - |
- Roivant Sciences Ltd.
- Healthcare median
Show the numbers
| Year | Roivant Sciences Ltd. | Healthcare median |
|---|---|---|
| FY26 | −3629.2% | −11.1% |
| FY25 | −592% | −30.6% |
| FY24 | 13294.2% | −47% |
| FY23 | −3200.2% | −58% |
| FY22 | −1528.9% | −80.4% |
| FY21 | −3400.9% | −71.9% |
| FY20 | - | −62.2% |